Cancer treatment

Under an exclusive agreement, Jazz Pharmaceuticals will acquire development and commercialisation rights to Zymeworks’ zanidatamab across all indications and all territories except for those Asia/Pacific territories previously licensed by Zymeworks. Zymeworks will receive a $50 million upfront payment, a second payment of $325 million, at Jazz’s option, and further potential regulatory and commercial milestones up […]

A new genetically engineered herpes virus has delivered a one-two punch against advanced cancers in initial findings from a Phase I trial. Researchers have found that RP2 – a modified version of the herpes simplex virus – showed signs of effectiveness in a quarter of patients with a range of advanced cancers. Patients on the […]

An experimental combination of two drugs halts the progression of small cell lung cancer, the deadliest form of lung cancer, according to a recent study. The discovery was made by researchers at Washington University School of Medicine in St Louis, Grenoble Alpes University in Grenoble in France, and The University of Texas MD Anderson Cancer […]

Investment from Takeda ventures will fund the development of Zelluna Immunotherapy’s allogeneic T Cell Receptor Natural Killer (TCR-NK) cells for the treatment of cancer. The funds will enable the advancement of a lead TCR-NK product through manufacturing to Clinical Trial Application (CTA) / Investigational New Drug Application (IND) readiness and, continue the advancement of Zelluna’s […]